<p>Keybank National Association OH 在最近向证券交易委员会提交的 13F 表格中表示，在第三季度将其在 Lantheus Holdings, Inc. (NASDAQ:LNTH - 免费报告) 的持仓削减了 63.7%。该基金在季度内出售了 327,696 股后，持有 187,026 股该医疗设备提供商的股票。截至最近的 SEC 文件，Keybank National Association OH 持有 Lantheus 0.28% 的股份，价值 9,593,000 美元。</p>
<ul>
<li>制药行业抛售：RSI 指标显示的 3 只股票你不应忽视</li>
</ul>
<p>其他几家对冲基金和机构投资者最近也对该公司的持仓进行了调整。Wealth Enhancement Advisory Services LLC 在第二季度将其在 Lantheus 的持股增加了 77.8%。Wealth Enhancement Advisory Services LLC 目前持有 6,159 股该医疗设备提供商的股票，价值 495,000 美元，此前在上个季度又购买了 2,695 股。Janney Montgomery Scott LLC 在第二季度将其在 Lantheus 的持仓增加了 17.5%。Janney Montgomery Scott LLC 目前持有 31,388 股该医疗设备提供商的股票，价值 2,569,000 美元，此前在该期间又收购了 4,677 股。Truist Financial Corp 在第二季度将其在 Lantheus 的持仓增加了 6.1%。Truist Financial Corp 目前持有 6,696 股该医疗设备提供商的股票，价值 548,000 美元，此前在该期间又收购了 382 股。Empirical Financial Services LLC 以 Empirical Wealth Management 名义在第二季度将其在 Lantheus 的股份增加了 25.4%。Empirical Financial Services LLC 以 Empirical Wealth Management 名义目前持有 4,984 股该医疗设备提供商的股票，价值 408,000 美元，此前在上个季度又收购了 1,009 股。最后，Hardy Reed LLC 在第二季度将其在 Lantheus 的持仓增加了 97.3%。Hardy Reed LLC 目前持有 23,000 股该医疗设备提供商的股票，价值 1,882,000 美元，此前在该期间又购买了 11,340 股。99.06% 的股票目前由机构投资者持有。</p>
<h2>Lantheus 股票表现</h2>
<p>NASDAQ:LNTH 周一开盘价为 66.92 美元。该公司的速动比率为 2.49，流动比率为 2.67，债务与股本比率为 0.51。Lantheus Holdings, Inc. 的 12 个月最低价为 47.25 美元，最高价为 111.29 美元。该公司的 50 日移动平均线为 64.87 美元，200 日移动平均线为 59.77 美元。该公司的市值为 44.4 亿美元，市盈率为 28.12，贝塔值为 -0.08。</p>
<ul>
<li>大规模突破：该 ETF 显示小型股的巨大收益信号</li>
</ul>
<p>Lantheus (NASDAQ:LNTH - 获取免费报告) 最近在 11 月 6 日发布了其财报。该医疗设备提供商报告每股收益 (EPS) 为 1.27 美元，符合市场共识预期的 1.27 美元。Lantheus 的净利润率为 10.99%，股本回报率为 30.88%。该公司在本季度的收入为 3.8401 亿美元，而分析师预期为 3.6342 亿美元。在去年同期，该公司每股收益为 1.70 美元。Lantheus 的收入同比增长了 1.4%。Lantheus 将其 2025 财年的指导目标设定为每股收益 5.500-5.650。作为一个整体，卖方分析师预计 Lantheus Holdings, Inc. 本年度将发布每股收益 6.01 美元。</p>
<h2>分析师评级变动</h2>
<p>一些分析师最近对 LNTH 股票发表了看法。瑞穗证券将 Lantheus 的目标价从 60.00 美元上调至 72.00 美元，并在 12 月 17 日的报告中给予该公司 “跑赢大盘” 的评级。Truist Financial 将 Lantheus 的目标价从 80.00 美元上调至 82.00 美元，并在 12 月 18 日的研究报告中给予该公司 “买入” 评级。高盛集团在 10 月 8 日的研究报告中将 Lantheus 的目标价设定为 77.00 美元，并给予该股票 “中性” 评级。最后，Weiss Ratings 在 1 月 6 日的报告中将 Lantheus 的评级从 “卖出 (d+)” 上调至 “持有 (c-)”。五位分析师对该股票给予了 “买入” 评级，三位分析师对该股票给予了 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 78.00 美元。</p>
<ul>
<li>这些医疗设备制造商是否准备好反弹？</li>
</ul>
<p><strong>阅读我们对 LNTH 的最新分析</strong></p>
<h2>Lantheus 公司简介</h2>
<p>(免费报告)</p>
<p>Lantheus Holdings, Inc. 是一家全球生命科学公司，专注于诊断成像剂和放射药物的开发、生产和商业化。公司总部位于马萨诸塞州北比勒里卡，Lantheus 专注于增强心血管和肿瘤疾病的检测和管理的产品。公司的产品组合包括超声增强剂、正电子发射断层扫描 (PET) 的分子成像示踪剂，以及旨在将诊断和治疗应用相结合的新兴治疗平台。</p>
<p>诊断成像部门包括超声对比剂，如 DEFINITY® (脂质微球) 和 Sonazoid® (氟丁烷)，这些对比剂改善了心脏结构和血流的可视化。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 Lantheus</li>
<li>特朗普刚刚签署了它</li>
<li>黄金警报</li>
<li>什么费用可以从资本利得税中扣除？</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>黄金市场崩溃的那一天</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUxOVEg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUxOVEg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Lantheus 吗？</h2>
<p>在考虑 Lantheus 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Lantheus 并不在名单上。</p>
<p>虽然 Lantheus 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

标普全球医疗股指数 ETF - iShares

医疗业 ETF - SPDR

生物科技 ETF - VanEck Vectors

<p>Keybank National Association OH 在第三季度减少了对 Lantheus Holdings, Inc. (NASDAQ:LNTH) 的持股比例，减持幅度为 63.7%，出售了 327,696 股。出售后，其持有 187,026 股，估值约为 960 万美元。其他机构投资者也调整了他们的持仓，其中 Wealth Enhancement Advisory Services 和 Janney Montgomery Scott 的增持尤为显著。Lantheus 报告第三季度每股收益为 1.27 美元，符合预期，营收为 3.8401 亿美元。分析师对该股票的评级不一，普遍目标价为 78.00 美元</p>

<p>Keybank National Association OH cut its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 63.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 187,026 shares of the medical equipment provider's stock after selling 327,696 shares during the quarter. Keybank National Association OH owned 0.28% of Lantheus worth $9,593,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Keybank National Association OH 在最近向证券交易委员会提交的 13F 表格中表示，在第三季度将其在 Lantheus Holdings, Inc. (NASDAQ:LNTH - 免费报告) 的持仓削减了 63.7%。该基金在季度内出售了 327,696 股后，持有 187,026 股该医疗设备提供商的股票。截至最近的 SEC 文件，Keybank National Association OH 持有 Lantheus 0.28% 的股份，价值 9,593,000 美元。</p>
</div><ul>
<li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li>
</ul>
<div class="lb-trans"><ul>
<li>制药行业抛售：RSI 指标显示的 3 只股票你不应忽视</li>
</ul>
</div><p>Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC raised its holdings in Lantheus by 77.8% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,159 shares of the medical equipment provider's stock valued at $495,000 after buying an additional 2,695 shares during the last quarter. Janney Montgomery Scott LLC increased its position in Lantheus by 17.5% in the 2nd quarter. Janney Montgomery Scott LLC now owns 31,388 shares of the medical equipment provider's stock valued at $2,569,000 after acquiring an additional 4,677 shares during the period. Truist Financial Corp increased its position in Lantheus by 6.1% in the 2nd quarter. Truist Financial Corp now owns 6,696 shares of the medical equipment provider's stock valued at $548,000 after acquiring an additional 382 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in shares of Lantheus by 25.4% during the second quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 4,984 shares of the medical equipment provider's stock valued at $408,000 after acquiring an additional 1,009 shares during the last quarter. Finally, Hardy Reed LLC lifted its holdings in shares of Lantheus by 97.3% during the second quarter. Hardy Reed LLC now owns 23,000 shares of the medical equipment provider's stock worth $1,882,000 after purchasing an additional 11,340 shares during the period. 99.06% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也对该公司的持仓进行了调整。Wealth Enhancement Advisory Services LLC 在第二季度将其在 Lantheus 的持股增加了 77.8%。Wealth Enhancement Advisory Services LLC 目前持有 6,159 股该医疗设备提供商的股票，价值 495,000 美元，此前在上个季度又购买了 2,695 股。Janney Montgomery Scott LLC 在第二季度将其在 Lantheus 的持仓增加了 17.5%。Janney Montgomery Scott LLC 目前持有 31,388 股该医疗设备提供商的股票，价值 2,569,000 美元，此前在该期间又收购了 4,677 股。Truist Financial Corp 在第二季度将其在 Lantheus 的持仓增加了 6.1%。Truist Financial Corp 目前持有 6,696 股该医疗设备提供商的股票，价值 548,000 美元，此前在该期间又收购了 382 股。Empirical Financial Services LLC 以 Empirical Wealth Management 名义在第二季度将其在 Lantheus 的股份增加了 25.4%。Empirical Financial Services LLC 以 Empirical Wealth Management 名义目前持有 4,984 股该医疗设备提供商的股票，价值 408,000 美元，此前在上个季度又收购了 1,009 股。最后，Hardy Reed LLC 在第二季度将其在 Lantheus 的持仓增加了 97.3%。Hardy Reed LLC 目前持有 23,000 股该医疗设备提供商的股票，价值 1,882,000 美元，此前在该期间又购买了 11,340 股。99.06% 的股票目前由机构投资者持有。</p>
</div><h2>Lantheus Stock Performance</h2>
<div class="lb-trans"><h2>Lantheus 股票表现</h2>
</div><p>NASDAQ:LNTH opened at $66.92 on Monday. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $111.29. The company has a fifty day moving average of $64.87 and a 200-day moving average of $59.77. The firm has a market capitalization of $4.44 billion, a P/E ratio of 28.12 and a beta of -0.08.</p>
<div class="lb-trans"><p>NASDAQ:LNTH 周一开盘价为 66.92 美元。该公司的速动比率为 2.49，流动比率为 2.67，债务与股本比率为 0.51。Lantheus Holdings, Inc. 的 12 个月最低价为 47.25 美元，最高价为 111.29 美元。该公司的 50 日移动平均线为 64.87 美元，200 日移动平均线为 59.77 美元。该公司的市值为 44.4 亿美元，市盈率为 28.12，贝塔值为 -0.08。</p>
</div><ul>
<li>Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>大规模突破：该 ETF 显示小型股的巨大收益信号</li>
</ul>
</div><p>Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.27. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The business had revenue of $384.01 million for the quarter, compared to analyst estimates of $363.42 million. During the same period in the prior year, the firm earned $1.70 earnings per share. Lantheus's revenue was up 1.4% on a year-over-year basis. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.</p>
<div class="lb-trans"><p>Lantheus (NASDAQ:LNTH - 获取免费报告) 最近在 11 月 6 日发布了其财报。该医疗设备提供商报告每股收益 (EPS) 为 1.27 美元，符合市场共识预期的 1.27 美元。Lantheus 的净利润率为 10.99%，股本回报率为 30.88%。该公司在本季度的收入为 3.8401 亿美元，而分析师预期为 3.6342 亿美元。在去年同期，该公司每股收益为 1.70 美元。Lantheus 的收入同比增长了 1.4%。Lantheus 将其 2025 财年的指导目标设定为每股收益 5.500-5.650。作为一个整体，卖方分析师预计 Lantheus Holdings, Inc. 本年度将发布每股收益 6.01 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of analysts recently weighed in on LNTH shares. Mizuho increased their price objective on Lantheus from $60.00 to $72.00 and gave the company an &#34;outperform&#34; rating in a report on Wednesday, December 17th. Truist Financial increased their price target on Lantheus from $80.00 to $82.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, December 18th. The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the stock a &#34;neutral&#34; rating in a research note on Wednesday, October 8th. Finally, Weiss Ratings upgraded Lantheus from a &#34;sell (d+)&#34; rating to a &#34;hold (c-)&#34; rating in a report on Tuesday, January 6th. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $78.00.</p>
<div class="lb-trans"><p>一些分析师最近对 LNTH 股票发表了看法。瑞穗证券将 Lantheus 的目标价从 60.00 美元上调至 72.00 美元，并在 12 月 17 日的报告中给予该公司 “跑赢大盘” 的评级。Truist Financial 将 Lantheus 的目标价从 80.00 美元上调至 82.00 美元，并在 12 月 18 日的研究报告中给予该公司 “买入” 评级。高盛集团在 10 月 8 日的研究报告中将 Lantheus 的目标价设定为 77.00 美元，并给予该股票 “中性” 评级。最后，Weiss Ratings 在 1 月 6 日的报告中将 Lantheus 的评级从 “卖出 (d+)” 上调至 “持有 (c-)”。五位分析师对该股票给予了 “买入” 评级，三位分析师对该股票给予了 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 78.00 美元。</p>
</div><ul>
<li>Are These Medical Device Makers Getting Ready To Rally?</li>
</ul>
<div class="lb-trans"><ul>
<li>这些医疗设备制造商是否准备好反弹？</li>
</ul>
</div><p><strong>Read Our Latest Analysis on LNTH</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 LNTH 的最新分析</strong></p>
</div><h2>Lantheus Company Profile</h2>
<div class="lb-trans"><h2>Lantheus 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company's portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.</p>
<div class="lb-trans"><p>Lantheus Holdings, Inc. 是一家全球生命科学公司，专注于诊断成像剂和放射药物的开发、生产和商业化。公司总部位于马萨诸塞州北比勒里卡，Lantheus 专注于增强心血管和肿瘤疾病的检测和管理的产品。公司的产品组合包括超声增强剂、正电子发射断层扫描 (PET) 的分子成像示踪剂，以及旨在将诊断和治疗应用相结合的新兴治疗平台。</p>
</div><p>The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.</p>
<div class="lb-trans"><p>诊断成像部门包括超声对比剂，如 DEFINITY® (脂质微球) 和 Sonazoid® (氟丁烷)，这些对比剂改善了心脏结构和血流的可视化。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Lantheus</li>
<li>Trump just signed it</li>
<li>GOLD ALERT</li>
<li>What Expenses Can Be Deducted From Capital Gains Tax?</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>The day the gold market broke</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Lantheus</li>
<li>特朗普刚刚签署了它</li>
<li>黄金警报</li>
<li>什么费用可以从资本利得税中扣除？</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>黄金市场崩溃的那一天</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TE5USA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=LNTH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lantheus Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Lantheus 吗？</h2>
</div><p>Before you consider Lantheus, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Lantheus 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantheus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Lantheus 并不在名单上。</p>
</div><p>While Lantheus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Lantheus 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Keybank National Association OH Sells 327,696 Shares of Lantheus Holdings, Inc. $LNTH

Market Beat

医疗业 ETF - Vanguard

基因改革 ETF - ARK

纽交所高增长板生物技术指数 ETF - First Trust

美国制药 ETF - iShares

Lantheus控股

2 倍做多纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

Keybank National Association OH 出售了 327,696 股 Lantheus 控股公司的股票，股票代码为$LNTH